Chen X, Guo Q, Chen X, Zheng W, Kang Y, Cao D
BMC Med Imaging. 2024; 24(1):48.
PMID: 38373912
PMC: 10877902.
DOI: 10.1186/s12880-024-01225-4.
Rosati A, Vargiu V, Certelli C, Arcieri M, Vizza E, Legge F
J Cancer Res Clin Oncol. 2023; 149(9):6479-6488.
PMID: 36773091
PMC: 10356890.
DOI: 10.1007/s00432-023-04594-5.
Terblanche L, Botha M
PLoS One. 2022; 17(7):e0271526.
PMID: 35862371
PMC: 9302809.
DOI: 10.1371/journal.pone.0271526.
Romeo C, Le Saux O, Jacobs M, Joly F, Ferron G, Favier L
Cancers (Basel). 2022; 14(2).
PMID: 35053517
PMC: 8773830.
DOI: 10.3390/cancers14020354.
Powell M, Filiaci V, Hensley M, Huang H, Moore K, Tewari K
J Clin Oncol. 2022; 40(9):968-977.
PMID: 35007153
PMC: 8937015.
DOI: 10.1200/JCO.21.02050.
In vitro effects of FBXW7 mutation in serous endometrial cancer: Increased levels of potentially druggable proteins and sensitivity to SI-2 and dinaciclib.
Urick M, Bell D
Mol Carcinog. 2018; 57(11):1445-1457.
PMID: 29963728
PMC: 6168387.
DOI: 10.1002/mc.22867.
Clinical significance of radiotherapy in patients with primary uterine carcinosarcoma: a multicenter retrospective study (KROG 13-08).
Cha J, Kim Y, Park W, Kim H, Kim J, Kim J
J Gynecol Oncol. 2016; 27(6):e58.
PMID: 27550404
PMC: 5078821.
DOI: 10.3802/jgo.2016.27.e58.
Outcome and Predictive Factors in Uterine Carcinosarcoma Using Postoperative Radiotherapy: A Rare Cancer Network Study.
Zwahlen D, Schick U, Bolukbasi Y, Thariat J, Abdah-Bortnyak R, Kuten A
Rare Tumors. 2016; 8(2):6052.
PMID: 27441069
PMC: 4935818.
DOI: 10.4081/rt.2016.6052.
Case report of uterine carcinosarcoma with incisional site recurrence.
Katke R, Nikam D, Bhansali M, Smruti B
J Obstet Gynaecol India. 2014; 64(Suppl 1):92-4.
PMID: 25404826
PMC: 4228021.
DOI: 10.1007/s13224-012-0345-3.
Evaluation of postoperative chemotherapy in patients with uterine carcinosarcoma: a retrospective survey of the Tohoku Gynecologic Cancer Unit.
Otsuki A, Otsuki T, Tokunaga H, Niikura H, Nagase S, Sugiyama T
Int J Clin Oncol. 2014; 20(3):574-8.
PMID: 25030547
DOI: 10.1007/s10147-014-0732-0.
Paclitaxel-carboplatin for advanced or recurrent carcinosarcoma of the uterus: the Japan Uterine Sarcoma Group and Tohoku Gynecologic Cancer Unit Study.
Takano T, Otsuki T, Tokunaga H, Toyoshima M, Utsunomiya H, Nagase S
Int J Clin Oncol. 2014; 19(6):1052-8.
PMID: 24395448
DOI: 10.1007/s10147-013-0658-y.
Adjuvant radiotherapy and/or chemotherapy after surgery for uterine carcinosarcoma.
Galaal K, van der Heijden E, Godfrey K, Naik R, Kucukmetin A, Bryant A
Cochrane Database Syst Rev. 2013; (2):CD006812.
PMID: 23450572
PMC: 6457622.
DOI: 10.1002/14651858.CD006812.pub3.
The influence of adjuvant radiotherapy on patterns of failure and survivals in uterine carcinosarcoma.
Park H, Kim H, Wu H, Kim H, Ha S, Kang S
Radiat Oncol J. 2012; 29(4):228-35.
PMID: 22984675
PMC: 3429907.
DOI: 10.3857/roj.2011.29.4.228.
Uterine carcinosarcomas (malignant mixed müllerian tumours): a review with special emphasis on the controversies in management.
Kanthan R, Senger J
Obstet Gynecol Int. 2011; 2011:470795.
PMID: 22007228
PMC: 3189599.
DOI: 10.1155/2011/470795.
Comparison of survival outcomes between patients with malignant mixed mullerian tumors and high-grade endometrioid, clear cell, and papillary serous endometrial cancers.
Felix A, Stone R, Bowser R, Chivukula M, Edwards R, Weissfeld J
Int J Gynecol Cancer. 2011; 21(5):877-84.
PMID: 21666484
PMC: 3827731.
DOI: 10.1097/IGC.0b013e31821a62dd.
Adjuvant radiotherapy and/or chemotherapy after surgery for uterine carcinosarcoma.
Galaal K, Godfrey K, Naik R, Kucukmetin A, Bryant A
Cochrane Database Syst Rev. 2011; (1):CD006812.
PMID: 21249682
PMC: 4161119.
DOI: 10.1002/14651858.CD006812.pub2.
MicroRNA signatures differentiate uterine cancer tumor subtypes.
Ratner E, Tuck D, Richter C, Nallur S, Patel R, Schultz V
Gynecol Oncol. 2010; 118(3):251-7.
PMID: 20542546
PMC: 2918705.
DOI: 10.1016/j.ygyno.2010.05.010.
Phase II evaluation of paclitaxel and carboplatin in the treatment of carcinosarcoma of the uterus: a Gynecologic Oncology Group study.
Powell M, Filiaci V, Rose P, Mannel R, Hanjani P, DeGeest K
J Clin Oncol. 2010; 28(16):2727-31.
PMID: 20421537
PMC: 2881851.
DOI: 10.1200/JCO.2009.26.8326.
How to deal with prognostic factors and radiotherapy results in uterine neoplasms with a sarcomatous component?.
Rovirosa A, Ascaso C, Ordi J, Arenas M, Valduvieco I, Lejarcegui J
Clin Transl Oncol. 2009; 11(10):681-7.
PMID: 19828411
DOI: 10.1007/s12094-009-0424-9.
Treatment of early uterine sarcomas: disentangling adjuvant modalities.
Zagouri F, Dimopoulos A, Fotiou S, Kouloulias V, Papadimitriou C
World J Surg Oncol. 2009; 7:38.
PMID: 19356236
PMC: 2674046.
DOI: 10.1186/1477-7819-7-38.